The five reported EpCAM/MSH2 co-mutation cases also showed early CRC (9–54 years), and Danish data reported brain cancers in 14% of LS families (mainly MSH2) (Therkildsen et al., 2015), compared to 3.7% in PLSD male MSH2 carriers. Here, MSH2 is linked to brain cancer.